A new substance that protects against a dangerous virus, almost without side-effects

May 9, 2014
Prof. Gerhard Ehninger, Managing Director. Credit: Christoph Reichelt

Letermovir keeps the ubiquitous Cytomegalovirus in check for weakened immune systems of infected transplant patients.

"In my whole research carrier, I have never seen anything like this in a highly active substance," said Prof. Gerhard Ehninger enthusiastically. The world-renowned Dresdner haematologist, Director of the University Cancer Center (UCC) of the University Clinic Carl Gustav Carus, Dresden, and of the German Stem Cell Donor Registry, was the Coordinating Investigator for a national and international study of the blocker letermovir. "Using letermovir, we block the release of replicating virus from the infected diseased cells," explained Prof. Ehninger. At a , the substance's activity has no effect upon other processes in the body. The substance's almost side-effect free activity could be impressively demonstrated in a controlled, double-blind study: for the first time the placebo affect could be examined here meaning that letermovir is so well tolerated by the weakened body that even fewer side-effects were observed than in patients who received no active treatment.

Today (May 8th 2014), the leading medical journal The New England Journal of Medicine published the ground-breaking results from the German and US research team. The edition's editorial also focused on the work in detail - A sign of the quality and importance of this study.

This substance effectively suppresses cytomegalovirus, also known as human herpes-virus 5. The virus is harmless for healthy people but highly dangerous for the immune-suppressed. "This evolutionarily ancient virus cannot be destroyed within the body," explained Prof. Ehninger. Because of this completely new mechanism of action at a cellular level, the severe side-effects that are seen with current medications are no longer observed. For this reason, patients can be treated with letermovir even on the day of bone marrow transplantation and fight the virus earlier – because of the side-effects caused by current drugs, this was previously only possible on day 30 after transplantation, in order to minimise the risk to the already weakened patient.

A new infection or the reactivation of a pre-existing cytomegalovirus infection can lead to serious problems in an immune-suppressed person. It can lead to CMV-associated inflammation of the bowel with severe diarrhoea, or inflammation of the liver or lungs. For a kidney transplant patient, CMV reactivation could lead to reduced functioning in the transplanted organ or even to loss of the transplant. Indeed, the virus attacks the retina and leads to blindness in 30% of AIDS patients not receiving highly active antiretroviral therapy. Furthermore, infection with cytomegalovirus is also associated with severe liver and lung diseases, hypertension and arteriosclerosis.

The active ingredient, letermovir, which was tested in an extensive clinical study by scientists in Dresden, Houston, Wuppertal, Münster, Würzburg, Iowa, Chicago and Stanford, sponsored by the company AiCuris, acts upon a different site to that used by current anti-virals which act upon the DNA polymerase i.e., upon the replication of the virus DNA by switching off a particular protein. However, this protein is also used in the rest of the body, not only for virus replication. In some cases, this leads to profound side-effects such as supressing the generation of new blood cells or damaging kidney function.

Through this multicentre study it also became apparent that virus testing must be more strongly standardised in line with the World Health Organisation (WHO) guidelines. In a few cases, blood samples taken during study were diagnosed negative for virus replication in the clinic, however in the central study laboratory precisely this reactivation could be shown. A reliable and precise measurement of this parameter is essential for proper and timely treatment with antiviral drug.

Explore further: Risk of cytomegalovirus infection following lung transplant now more measurable

More information: "Letermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation;" Roy F. Chemaly, M.D., Andrew J. Ullmann, M.D., Susanne Stoelben, M.D., Marie Paule Richard, M.D., Martin Bornhäuser, M.D., Christoph Groth, M.D., Hermann Einsele, M.D., Margarida Silverman, M.D., Kathleen M. Mullane, M.D., Janice Brown, M.D., Horst Nowak, Ph.D., Katrin Kölling, M.Sc., Hans P. Stobernack, D.V.M., Peter Lischka, Ph.D., Holger Zimmermann, Ph.D., Helga Rübsamen-Schaeff, Ph.D., Richard E. Champlin, M.D., and Gerhard Ehninger, M.D., New England Journal of Medicine, May 8, 2014, vol. 370, no. 19:
DOI: 10.1056/NEJMoa1309533

Related Stories

Risk of cytomegalovirus infection following lung transplant now more measurable

June 25, 2012
(Medical Xpress) -- Researchers in the Department of Virology and the Clinical Department of Thoracic Surgery at the MedUni Vienna have demonstrated that the risk of cytomegalovirus infection following lung transplant can ...

Finding hiding place of virus could lead to new treatments

March 11, 2014
Discovering where a common virus hides in the body has been a long-term quest for scientists. Up to 80 percent of adults harbor the human cytomegalovirus (HCMV), which can cause severe illness and death in people with weakened ...

People with leukaemia are more prone to infection – but not from one particular herpes virus

March 19, 2014
People with chronic lymphocytic leukaemia (CLL) are essentially more prone to infections such as varicella, influenza or pneumococci due to the reduction in the number of antibodies that their condition causes. Researchers ...

Common virus may cause anemia in patients with kidney disease

April 10, 2014
A virus that is present in most people in a latent state may induce or exacerbate anemia in patients with kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology ...

New vaccine hope for leading viral cause of birth defects

April 10, 2014
(Medical Xpress)—Experts in infection and immunity have made a path-finding discovery that could lead to the development of a vaccine for a health-ravaging virus that affects around 50% of adults in the UK.

Novel drug prevents common viral disease in stem-cell transplant patients, study finds

September 25, 2013
A new drug can often prevent a common, sometimes severe viral disease in patients receiving a transplant of donated blood-making stem cells, a clinical trial led by researchers at Dana-Farber Cancer Institute and Brigham ...

Recommended for you

A large-scale 'germ trap' solution for hospitals

July 26, 2017
When an infectious airborne illness strikes, some hospitals use negative pressure rooms to isolate and treat patients. These rooms use ventilation controls to keep germ-filled air contained rather than letting it circulate ...

Male hepatitis B patients suffer worse liver ailments, regardless of lifestyle

July 25, 2017
Why men with hepatitis B remain more than twice as likely to develop severe liver disease than women remains a mystery, even after a study led by a recent Drexel University graduate took lifestyle choices and environments ...

Researchers report new system to study chronic hepatitis B

July 25, 2017
Scientists from Princeton University's Department of Molecular Biology have successfully tested a cell-culture system that will allow researchers to perform laboratory-based studies of long-term hepatitis B virus (HBV) infections. ...

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Research examines lung cell turnover as risk factor and target for treatment of influenza pneumonia

July 24, 2017
Influenza is a recurring global health threat that, according to the World Health Organization, is responsible for as many as 500,000 deaths every year, most due to influenza pneumonia, or viral pneumonia. Infection with ...

Scientists propose novel therapy to lessen risk of obesity-linked disease

July 24, 2017
With obesity related illnesses a global pandemic, researchers propose in the Journal of Clinical Investigation using a blood thinner to target molecular drivers of chronic metabolic inflammation in people eating high-fat ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.